Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2–4 Years with Rett Syndrome
PopPK model-based simulations confirm that the weight-banded dosing regimen used in DAFFODIL is adequate to achieve target trofinetide exposure in 2- to 4-year-olds with RTT.
Authors
- Heather Bradley (ORCID: https://orcid.org/0000-0002-7667-4197)
- Kelly Maxwell
- Julie Passarell (ORCID: https://orcid.org/0000-0002-2034-6274)
- Kathie M. Bishop
- Mona Darwish
- James M. Youakim (ORCID: https://orcid.org/0000-0001-5551-8956)
Institutions
- Acadia Pharmaceuticals (United States) (US)
- Simulations Plus (United States) (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1007/s12325-024-03058-7
- Citations
- 1
- Primary Topic
- Genetics and Neurodevelopmental Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.55
Funders
- ACADIA Pharmaceuticals